## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($121.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Brendel Financial Advisors LLC Sells 23,978 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20251231T103517 | Somewhat-Bullish | Relevance: 100%
- Brendel Financial Advisors LLC decreased its holdings in Abbott Laboratories by 75.4% in Q3, selling 23,978 shares and leaving it with 7,816 shares valued at $1.05 million. Meanwhile, major institutions like Vanguard and Norges Bank significantly increased their stakes in ABT. Abbott reported Q3 EPS of $1.30, with revenue slightly below forecasts, issued FY2025 guidance of $5.12-$5.18 EPS, and raised its quarterly dividend to $0.63.

**2. Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus**
- Source: ts2.tech | 20251231T011156 | Bullish | Relevance: 100%
- Abbott shares rose marginally as investors focused on two key catalysts: an SEC filing from acquisition target Exact Sciences detailing accelerated bonus payouts tied to "golden parachute" tax rules for its proposed deal with Abbott, and the ongoing U.S. rollout of Abbott's Volt pulsed field ablation system for atrial fibrillation. These developments are influencing the company's valuation as the year-end approaches, with market participants closely monitoring the deal's progress, Volt's commercial uptake, and Abbott's upcoming earnings report.

**3. Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment**
- Source: Finviz | 20251230T174600 | Bullish | Relevance: 100%
- Abbott Laboratories (ABT) has received FDA approval for its Voltâ„¢ PFA System, designed to treat patients with atrial fibrillation (AFib). This system will soon be commercially available in the U.S. and is already expanding in the EU after CE Mark approval. The approval follows the VOLT-AF IDE study, which demonstrated the system's safety and effectiveness for both paroxysmal and persistent AFib.

**4. Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock**
- Source: Yahoo Finance Singapore | 20251231T140725 | Neutral | Relevance: 100%
- This article analyzes why Abbott Laboratories (ABT) is a trending stock, focusing on the importance of earnings estimate revisions for predicting stock performance. It details Abbott's current and projected earnings and revenue growth, its recent financial results, and its valuation, concluding with a Zacks Rank of #4 (Sell) indicating potential underperformance in the near term.

**5. VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 245,400 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20251231T115421 | Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al significantly increased its stake in Abbott Laboratories (NYSE:ABT) by acquiring an additional 245,400 shares, bringing its total holdings to 826,268 shares valued at $110.67 million. This makes Abbott Laboratories the 22nd biggest position for the institutional investor, comprising 0.7% of its total holdings. The article also details other institutional investor activities, analyst ratings, and the company's recent financial performance and dividend increase.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.1x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $218.1B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.1 |
| Current P/E | 24.2 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.1% to 0.4% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 48. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.42% (CS: 74) | Neutral |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 0.993x | Below |
| vs SMA200 | 0.963x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.28
- **Stop Loss:** $121.16 (3.3% risk)
- **Target:** $129.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 349
- **Position Value:** $43,722.72
- **Portfolio %:** 43.72%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*